{
  "id": 9158584,
  "title": "Viking shares surge on updated obesity drug data",
  "url": "https://urgent.news/2026/09/22/viking-shares-surge-on-updated-obesity-drug-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T16:10:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/viking-obesity-drug-maintenance-study-results/831004/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Yahoo Finance",
        "title": "Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.",
        "url": "https://urgent.news/2026/09/22/viking-therapeutics-skyrockets-on-obesity-drug-data-eli-lilly-novo",
        "published": "2026-09-22T11:48:01.000Z"
      },
      {
        "outlet": "Quartz",
        "title": "Viking's obesity drug data fuels bets it can rival Lilly's Zepbound",
        "url": "https://urgent.news/2026/09/22/vikings-obesity-drug-data-fuels-bets-it-can-rival-lillys-zepbound",
        "published": "2026-09-22T17:20:27.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}